Document is current
Any future updates will be listed below
-
Authors
Bivand, Joanna Małgorzata
Sivertsen, Audun
Tellevik, Marit Gjerde
Saebo, Oystein
Patel, Robin
Dyrhovden, Ruben
Kommedal, Øyvind
-
Funding
Funding for this research was provided by:
University of Bergen
- License Information
-
More Information
Article History
Received: 7 April 2026
Accepted: 22 July 2026
First Online: 28 July 2026
Declarations
Ethics approval and consent to participate: The study was approved by the regional ethics committee the “Regional Committee for Medical and Health Research Ethics for the western region of Norway” on 27.02.2024 with decision number 728299, and the research strictly adhered to the ethical standards of the World Medical Association Declaration of Helsinki. Due to the methodological design of the study, the requirement to obtain informed consent to participate was waived by the “Regional Committee for Medical and Health Research Ethics for the western region of Norway”.
Consent for publication: Not applicable.
Competing interests: Øyvind Kommedal is a co-founder and shareholder in Pathogenomix Inc. Oystein Saebo is a co-founder, shareholder, and the CTO of Pathogenomix Inc.
